Welcome to our dedicated page for Interpace Biosciences news (Ticker: IDXG), a resource for investors and traders seeking the latest updates and insights on Interpace Biosciences stock.
Interpace Biosciences, Inc. (IDXG) is a molecular diagnostics company whose news flow centers on personalized medicine, thyroid cancer testing, and capital structure developments. Through its Interpace Diagnostics subsidiary, the company reports on clinical use of its molecular diagnostic tests, particularly its thyroid-focused platform built around ThyGeNEXT and ThyraMIRv2, as well as on financial performance and strategic responses to reimbursement changes.
News updates frequently include quarterly and annual financial results, where Interpace discusses net revenue, test volumes, cash collections, gross profit metrics, and non-GAAP measures such as Adjusted EBITDA. These releases often highlight trends such as record thyroid test volume, growth in thyroid-related revenue, and the impact of operational initiatives, including the use of AI and automation in laboratory processes as described by the company.
Investors and clinicians following IDXG news will also see regulatory and reimbursement announcements, such as company responses to Medicare Local Coverage Determinations affecting its PancraGEN test and the resulting restructuring toward a thyroid-only diagnostics business. Interpace’s communications explain how coverage decisions influence its test portfolio and outline its plans to remain sustainable and profitable based on its thyroid testing franchise.
Another key category of news involves scientific and clinical data presentations. Interpace reports on posters and studies presented at professional meetings, including large real-world analyses of ThyGeNEXT and ThyraMIRv2 in indeterminate thyroid nodules and institutional experiences using archival cytology slides. These items describe how the company’s combination platform refines malignancy risk and supports physician decision-making, according to the data presented.
Capital and balance sheet updates also feature in IDXG news, including announcements about early repayment of a term loan facility with BroadOak Capital Partners. Readers who monitor this page can review a chronological record of these financial, clinical, and strategic developments as disclosed by Interpace in its press releases.
Interpace Biosciences (OTCID: IDXG) reported preliminary unaudited 2025 revenue of approximately $38–39 million, with $34–35 million from thyroid testing, a ~21% increase versus 2024. The company initiated full-year 2026 revenue guidance of ~$40 million, implying ~16% thyroid revenue growth versus 2025. All Series C preferred shares converted into common stock, resulting in issuance of ~23,267,327 common shares and a pro forma share count of ~27.7 million. Management reports the company is debt-free after paying off 100% of outstanding debt in December and intends to seek a Nasdaq uplisting in 2026, although no assurance of success is given.
Interpace Biosciences (OTCID: IDXG) announced on December 3, 2025 that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners prior to the facility's maturity date. The repayment satisfies obligations under the Loan and Security Agreement originally entered on October 29, 2021. By retiring the debt early, the company said it eliminates related interest expenses, increases operational flexibility, and strengthens its balance sheet to support future commercial growth. Management framed the move as part of a strategic turnaround to profitability and said the company continues to deliver record testing volumes and revenue for its thyroid tests.
Interpace Biosciences (OTCQX: IDXG) reported third quarter 2025 results for the period ended September 30, 2025. Net revenue was $8.8 million; cash collections were $10.0 million. The company said thyroid test volume rose 12% year‑over‑year and thyroid revenue reached a record $8.8M, up 22% versus a prior pro forma quarter, while average revenue per test increased 5%. Management reported income from continuing operations of $1.0 million and adjusted EBITDA of $1.3 million. The company noted a 22% reduction in days sales outstanding and additional principal payments on long‑term debt tied to stronger cash flow.
Interpace Biosciences (OTCQX: IDXG) presented two significant scientific posters at the 2025 American Thyroid Association Annual Meeting in Scottsdale, Arizona. The first poster demonstrated that their testing platform successfully yielded molecular results in 86% (56 out of 65) of thyroid FNA cases previously deemed insufficient by another platform, using archival cytology slides.
The second poster analyzed 28,144 indeterminate thyroid nodules, showing that ThyGeNEXT identified BRAF V600E-like alterations in 4-6% and RAS-like alterations in ~19% of cases, while 76-77% were mutation-negative. The ThyraMIRv2 microRNA profiling further refined malignancy risk assessment, with over 90% of mutation-negative nodules classified as low risk.
Interpace Biosciences (OTCQX:IDXG) reported mixed Q2 2025 financial results, with net revenue of $9.2 million, down 23% year-over-year. Despite overall revenue decline, the company achieved record thyroid testing performance, with volume up 16% and revenue up 25% year-over-year to $8.7 million.
The company reported a Q2 loss from continuing operations of $0.5 million, compared to income of $2.5 million in Q2 2024, primarily impacted by $1.2 million in one-time charges related to PancraGEN testing discontinuation. Cash collections remained strong at $10.8 million, and preliminary July 2025 revenue showed a 54% year-over-year increase to $3.3 million.
Interpace is transitioning to focus exclusively on thyroid testing, following the loss of PancraGEN reimbursement. The company maintains a positive outlook for Q3 2025 and beyond as a thyroid-only diagnostics business.
Interpace Biosciences (OTCQX: IDXG) reported strong financial results for Q1 2025, with revenue reaching $11.5 million, a 13% increase year-over-year. The company achieved record thyroid test revenue of $8.0M (up 19%) and record thyroid test volume (up 16%). Cash collections hit record levels at $11.3 million, up 10% from the previous year.
Key financial metrics showed significant improvement, with gross profit margin increasing to 64% from 62%, and income from continuing operations reaching $1.8 million, a $0.9 million improvement over Q1 2024. The company initiated full-year 2025 revenue guidance of approximately $38 million, despite the anticipated loss of PancraGEN revenue after May 2, 2025.
Interpace Diagnostics (OTCQX: IDXG) announced the discontinuation of their PancraGEN® molecular diagnostic test for pancreatic cyst cancer risk assessment, effective May 2, 2025. This decision follows the Medicare Administrative Contractor Novitas Solutions' Local Coverage Determination ending reimbursement for the test.
The company will stop accepting specimens for PancraGEN testing after May 2, 2025, though they will continue processing tests without reimbursement between April 24 and May 2, 2025, to manage the transition. Despite PancraGEN's decade-long use in aiding pancreatic cancer diagnosis and reducing unnecessary surgeries, the loss of Medicare reimbursement makes the service unsustainable.
Interpace expects to maintain profitability through its thyroid testing franchise, ThyGeNEXT® + ThyraMIR®v2, and will implement a restructuring plan to adapt to these changes.
Interpace Biosciences (IDXG) reported preliminary Q4 and full-year 2024 results, highlighting record-breaking performance across key metrics. The company achieved a 21% year-over-year increase in Q4 Molecular Volume and a 17% increase for the full year, leading to double-digit revenue growth in both periods.
The company reached all-time highs in test volume, revenue, income, and cash collections for both Q4 and FY2024. Their ThyGeNEXT® + ThyraMIR®v2 testing services for indeterminate thyroid nodules showed particularly strong physician demand, significantly contributing to profitability.
While maintaining a positive outlook for 2025, management acknowledged uncertainty regarding PancraGEN® Medicare reimbursement, but indicated preparedness for potential non-coverage determination, emphasizing the strength and profitability of their Endo business unit as a solid foundation.
Interpace Diagnostics (OTCQX: IDXG) announced that the Centers for Medicare & Medicaid Services (CMS) has delayed the implementation of the Genetic Testing for Oncology Local Coverage Determination (LCD) from February 23, 2025, to April 24, 2025. This delay affects PancraGEN®, a DNA-based molecular diagnostic test that assesses pancreatic cyst cancer risk.
The extension allows the incoming Trump administration to review the proposed policy changes and evaluate the clinical evidence for PancraGEN, which has been Medicare-covered for over 10 years and has helped more than 80,000 patients. The test helps physicians determine optimal treatment plans and reduce unnecessary surgeries.
While Interpace can sustain operations without PancraGEN through its thyroid nodule testing franchise (ThyGeNEXT® + ThyraMIR®v2), the delay allows the company to continue offering PancraGEN and related Point2® fluid chemistry tests while preserving jobs for employees involved in specimen processing.
Interpace Diagnostics (OTCQX: IDXG) announced it will discontinue its PancraGEN® molecular diagnostic test effective February 7, 2025, following a Centers for Medicare & Medicaid Services (CMS) decision to end coverage. The test, which has helped over 80,000 patients assess pancreatic cyst cancer risk since 2013, will no longer be viable as it primarily serves Medicare patients.
The decision comes through a final Local Coverage Determination (LCD) issued by CMS's Medicare Administrative Contractor, Novitas. According to CEO Tom Burnell, this decision may lead to unnecessary surgeries and increased healthcare costs. Despite this setback, Interpace expects to remain profitable through its thyroid nodule testing franchise, ThyGeNEXT® + ThyraMIR®v2.
FAQ
What is the current stock price of Interpace Biosciences (IDXG)?
What is the market cap of Interpace Biosciences (IDXG)?
